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Background: Although long-term treatment with ezetimibe+statin usually result in greater LDL-C reduction compared with statin monotherapy, the 
mechanism remains unclear.
Methods: 146 coronary artery disease patients whose LDL-C ≥70mg/dL after treatment with atorvastatin 10mg/day or rosuvastatin 2.5 mg/day 
(initial dose in Japan) were randomly assigned to ezetimibe 10mg/day + statin (E/S, n=75) or double-dose statin (D/S, n=71) and followed for 52 
weeks.
Results: Baseline patient’s characteristics including PCSK9 did not differ between E/S and D/S. From baseline to 12 weeks, LDL-C levels 
decreased in both 2 groups and the decrease in LDL-C levels was greater in E/S (-28±19 mg/dL vs -17±17 mg/dL, p<0.01). E/S maintained LDL-C 
levels after 12 weeks, whereas D/S presented an increase in LDL-C levels after 12 weeks. The ratio of campesterol/lathosterol level (as a cholesterol 
absorption/synthesis marker) showed the same transition as LDL-C levels in E/S. In contrast, it showed consistent increase in D/S until 52 weeks. 
PCSK9 levels at 12 weeks were higher in D/S than E/S (367±131 ng/mL vs 310±95 ng/mL, P<0.05), but they did not differ between 2 groups at 52 
weeks (Figure).
Conclusions: Although the difference in PCSK9 levels between 2 groups was transient, that in levels of the campesterol/lathosterol ratio grew until 
52 weeks. These results suggest the inhibition of cholesterol absorption by ezetimibe may be more contributed to stable and greater long-term LDL-C 
reduction compared with statin monotherapy.
